Pioneering Pain Management: High-Frequency Electrical Stimulation Devices

By HEOR Staff Writer

October 27, 2023

The Current Opioid Crisis and the Treatment of Post-Caesarean Pain

Systemic opioids are the medication that is utilised the most frequently, despite the fact that pain management following a caesarean delivery is a complicated issue. Having said that, this method is not without its flaws. The overprescription of opioids is a key cause, and it is estimated that 1.2 million of the caesarean births performed annually in the United States result in the disposal of 12 million unneeded tablets. There is a high likelihood that these unused tablets will be abused, which will contribute to the continuing opioid problem.

 

A Novel Technique for the Management of Pain

A recent study found that devices that use high-frequency electrical stimulation could be an effective solution to the problem. According to the findings of the study, women who had caesarean deliveries followed by transcutaneous treatment using a high-frequency electrical stimulation device required around 47 percent less opioid analgesic medication while they were in the hospital. In addition, these individuals reported levels of discomfort that were comparable to those reported by patients who had used a sham device.

High-frequency electrical stimulation devices

This breakthrough has the potential to constitute a key step towards lowering the use of opioids, avoiding overprescribing, and preventing dependence from developing. Because it is estimated that 36,000 to 72,000 people in the United States develop a dependence on opioids each year after having a caesarean delivery, finding effective measures to reduce opioid use continues to be a public health priority.

Reference url

Recent Posts

FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases

By HEOR Staff Writer

May 7, 2026

Truqap Prostate Cancer Therapy gains key backing from FDA advisors for PTEN-deficient metastatic hormone-sensitive prostate cancer, following strong data from the pivotal trial that demonstrated meaningful delays in disease progression. ODAC Backs Targeted Therapy The ...
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changing Landscape
EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe's complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organi...
Unlocking the Benefits of Cardiovascular Health Checks in EU Prevention Strategies
Cardiovascular health checks deliver strong clinical, economic and societal value when delivered as structured, risk-based programmes connected to ongoing care. This approach supports EU cardiovascular prevention strategies by catching cardiometabolic risks early and reducing long-term events. Th...